Compare PEO & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PEO | TECX |
|---|---|---|
| Founded | 1929 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 754.8M | 618.9M |
| IPO Year | N/A | 2018 |
| Metric | PEO | TECX |
|---|---|---|
| Price | $27.94 | $33.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $75.20 |
| AVG Volume (30 Days) | 57.1K | ★ 159.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 5.93% | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.75 | $14.39 |
| 52 Week High | $28.88 | $39.53 |
| Indicator | PEO | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 66.63 | 55.64 |
| Support Level | $25.37 | $27.30 |
| Resistance Level | $28.88 | $35.99 |
| Average True Range (ATR) | 0.48 | 2.07 |
| MACD | 0.08 | 0.58 |
| Stochastic Oscillator | 95.08 | 64.57 |
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in the petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.